| 4.73 0.14 (3.05%) | 03-09 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 6.34 | 1-year : | 7.26 |
| Resists | First : | 5.43 | Second : | 6.21 |
| Pivot price | 5.31  |
|||
| Supports | First : | 4.15 | Second : | 3.46 |
| MAs | MA(5) : | 4.59 |
MA(20) : | 5.42 |
| MA(100) : | 6.33  |
MA(250) : | 4 |
|
| MACD | MACD : | -0.4 |
Signal : | -0.4 |
| %K %D | K(14,3) : | 25.2 |
D(3) : | 23.7 |
| RSI | RSI(14): 36.5 |
|||
| 52-week | High : | 9.75 | Low : | 1.53 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ NUVB ] has closed above bottom band by 22.7%. Bollinger Bands are 5.6% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 4.73 - 4.77 | 4.77 - 4.79 |
| Low: | 4.37 - 4.4 | 4.4 - 4.43 |
| Close: | 4.54 - 4.6 | 4.6 - 4.64 |
Nuvation Bio Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutic candidates for oncology. The company's lead product candidate is NUV-422, a small molecule inhibitor targeting cyclin-dependent kinase (CDK)2, CDK4, and CDK6. It is also developing NUV-868, a selective oral small molecule BET inhibitor that epigenetically regulates proteins that control tumor growth and differentiation; NUV-569, a differentiated oral small molecule selective inhibitor of the Wee1 kinase for DNA damage repair; NUV-1182, an adenosine receptor inhibitor; and drug-drug conjugate (DDC) platform that focuses on targeting an inhibitor of poly ADP ribose polymerase (PARP) to anti-cancer warheads of existing drugs, as well as PARP inhibitor to address ER+ breast and ovarian cancer. The company was formerly known as RePharmation Inc. and changed its name to Nuvation Bio Inc. in April 2019. Nuvation Bio Inc. was founded in 2018 and is headquartered in New York, New York.
Fri, 06 Mar 2026
Kuehn Law Encourages Investors of Nuvation Bio Inc. to Contact Law Firm - PR Newswire
Thu, 05 Mar 2026
Truist Highlights Nuvation Bio’s (NUVB) Ibtrozi’s Robust Market Uptake and Lead Over Competitors - MSN
Wed, 04 Mar 2026
Nuvation Bio (NUVB) Generates $62.9M Annual Revenue Following Successful Erozi Launch - Yahoo Finance
Wed, 04 Mar 2026
Nuvation Bio Inc. (NYSE:NUVB) Q4 2025 Earnings Call Transcript - Insider Monkey
Wed, 04 Mar 2026
Nuvation Bio Inc. Shareholders Are Encouraged to Reach Out - GlobeNewswire
Wed, 04 Mar 2026
H.C. Wainwright Sticks to Its Buy Rating for Nuvation Bio (NUVB) - The Globe and Mail
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NYSE
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 342 (M) |
| Shares Float | 235 (M) |
| Held by Insiders | 18.7 (%) |
| Held by Institutions | 62.1 (%) |
| Shares Short | 48,830 (K) |
| Shares Short P.Month | 47,950 (K) |
| EPS | -0.5 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0.87 |
| Profit Margin | 0 % |
| Operating Margin | -81.4 % |
| Return on Assets (ttm) | -23.5 % |
| Return on Equity (ttm) | -53.2 % |
| Qtrly Rev. Growth | 633 % |
| Gross Profit (p.s.) | 0.15 |
| Sales Per Share | 0.18 |
| EBITDA (p.s.) | -0.62 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -173 (M) |
| Levered Free Cash Flow | -116 (M) |
| PE Ratio | -9.67 |
| PEG Ratio | 0 |
| Price to Book value | 5.38 |
| Price to Sales | 25.73 |
| Price to Cash Flow | -9.34 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|